proqr therapeutics nv nasdaq prqr dutch biotechnology company based leiden netherlands presence cambridge massachusetts company funded chief executive officer ceo daniel de boer specializes development rna therapeutics using rna editing platform technology called proqr founded chief executive officer ceo daniel de boer cofounders henri termeer dinko valerio gerard initial pipeline company develop smallmolecule drugs gene therapy would treat cystic fibrosis positive proof concept poc achieved clinical trial molecule targeting gene coding cystic fibrosis transmembrane conductance regulator cftcr subsequently company expanded pipeline treating rare diseases including diseases spinout proqr named amylon therapeutics established leiden focus development therapies central nervous proqr announced collaboration eli lilly company axiomer technology focused genetic disorders liver nervous system signed deal proqr would receive million million upfront equity investment relationship two firms deepened expansion indications engagement million cash infusion included equity company announced would focus exclusively advancing rna editing proqr rna editing company targeting genetic diseases focusing making changes firms rna editing technology called axiomer make targeted single nucleotide changes proqrs proprietary axiomer technology based short strands synthetic rna called editing oligonucleotides eons eons designed specifically bind target single stranded rna mimic double stranded structure normally attracts enzyme called adenosine deaminase acting rna adar eon attract adar specific location rna make atoi edit technology used correct rna diseasecausing mutation back normal rna change protein new function helps prevent treat disease companys pipeline includes discovery stage programs addressing areas high unmet medical need cholestatic diseases targeting ntcp cardiovascular disease targeting httpsenwikipediaorgwikiproqr